CRNX | tickerfilter.com

Fundamental analysis

21%

Profitability 25%

Dept financing 2%

Liquidity 50%

Performance 15%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

3.15%

1 Month

15.96%

3 Months

-27.36%

6 Months

-6.07%

1 Year

33.50%

2 Year

-7.34%

Key data

Stock price

$40.25

P/E Ratio

0.00

DAY RANGE

$40.00 - $40.88

EPS

-$4.95

52 WEEK RANGE

$25.83 - $57.99

52 WEEK CHANGE

$28.72

MARKET CAP

2.509 B

YIELD

N/A

SHARES OUTSTANDING

104.705 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

08-07-2025

BETA

1.77

PUBLIC FLOAT

AVERAGE 10 VOLUME

$847,704

AVERAGE 30 VOLUME

$1,139,905

Company detail

CEO: Scott R. Struthers
Region: US
Website: crinetics.com
Employees: 210
IPO year: 2018

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Crinetics Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism.

CRNX - Crinetics Pharmaceuticals, Inc.